Sui (SUI) is currently facing downward pressure with a slight decline in its value due to volatile market conditions. The token is currently trading at $1.64, marking a dip of 3.20% over the last 24 hours. However, the data from Bitwise revealed that Sui, a blockchain platform designed to make digital asset ownership fast, private, […]Sui (SUI) is currently facing downward pressure with a slight decline in its value due to volatile market conditions. The token is currently trading at $1.64, marking a dip of 3.20% over the last 24 hours. However, the data from Bitwise revealed that Sui, a blockchain platform designed to make digital asset ownership fast, private, […]

SUI Eyes Recovery Toward $1.85 in Sight as BITW ETF Boosts Confidence

2025/12/11 16:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • Sui’s inclusion in the Bitwise 10 Crypto Index ETF boosts its visibility among institutional investors.
  • Technical indicators show easing bearish momentum, hinting at a potential market recovery.
  • The token could target $1.85 if key support levels hold, signaling potential for further upward movement.

Sui (SUI) is currently facing downward pressure with a slight decline in its value due to volatile market conditions. The token is currently trading at $1.64, marking a dip of 3.20% over the last 24 hours.

However, the data from Bitwise revealed that Sui, a blockchain platform designed to make digital asset ownership fast, private, secure, and accessible, is gaining traction in the crypto space. Its high-performance infrastructure simplifies transactions and enhances user experience for both individuals and institutions. The platform’s focus on efficiency and privacy sets it apart in a crowded market.

It is a significant achievement that Sui has been listed on the Bitwise 10 Crypto Index ETF (NYSE: BITW), giving it the opportunity to reach institutional investors. This is a clear indication that there is confidence in the technology and market potential of Sui. Being listed on BITW means that Sui is among the top cryptos.

Also Read: SUI Eyes $4 Rally Following SEC Approval of First 2x Leveraged SUI ETF

Technical Outlook Suggests Weakening Bearish Strength

The above chart reveals that since the peak of $4.50+ in late 2024, the market has been trending continuously lower, forming lower highs and lower lows. More recently, it appears that the market is resisting the lower lows, ranging around the support level of $1.50-$1.60, with a slight recovery to $1.65, suggesting possible stabilization, though the trend is not yet fully reversed.

Source: TradingView

The RSI stands at 36.87, showing oversold levels but emerging signs of a recovery. However, the MACD is still bearish, with the MACD line at -0.45716 below the signal line at -0.27772, although the presence of smaller red bars on the histogram suggests that the pressure of selling is easing. Furthermore, SUI is presently on a slight recovery path from the lower levels but still combating bearish momentum.

SUI Could Surge to $1.85 if $1.45 Holds Strong

Moreover, the crypto analyst, Hailey LUNC, highlighted that SUI is also indicating a bullish turnaround because the downtrend line has been breached, and higher highs are being established. The critical resistance areas, which acted as obstacles for the price, have been regained, indicating that the buyers have started participating actively again. This is a classic indication of a bullish turnaround.

Source: Hailey LUNC

If SUI is able to maintain support above the critical level of $1.45, the next logical level that it should target will be $1.85. Traders will certainly keep their eyes on the critical level, hoping that it will trigger a breakout that will unleash the next level of price movement. If so, it appears that SUI is on the verge of starting a new long-term uptrend.

Also Read: SUI Momentum Builds: Grayscale ETF Filing Signals $10 Breakout Potential

Market Opportunity
SUI Logo
SUI Price(SUI)
$0.9123
$0.9123$0.9123
+1.37%
USD
SUI (SUI) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09